Mechanisms of heparin induced anti-cancer activity in experimental cancer models

Critical Reviews in Oncology/Hematology

Volumn 61, Issue 3, 2007, Pages 195-207

  Niers, T M H ^a   Klerk, C P W ^a   DiNisio, M ^a   Van Noorden, C J F ^a   Buller H R ^a   Reitsma, P H ^a   Richel, D J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Animal model; Anticoagulant activity; Cancer; Haematogenous metastases; Heparins; Low molecular weight heparin

Indexed keywords

HEPARANASE; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; PROTEOHEPARAN SULFATE; SELECTIN; TINZAPARIN;

ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING; CANCER; CANCER CELL; CANCER INHIBITION; CONTINUOUS INFUSION; DRUG MECHANISM; DRUG MEGADOSE; INOCULATION; LOW DRUG DOSE; METASTASIS; NONHUMAN; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GLUCURONIDASE; HEPARAN SULFATE PROTEOGLYCANS; HEPARIN; NEOPLASM METASTASIS; NEOPLASMS; SELECTINS;

EID: 33847291915     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.07.007     Document Type: Review

References (112)

1. Prandoni P., Lensing A.W., Buller H.R., et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339 (1992) 441-445
2. Hettiarachchi R.J., Smorenburg S.M., Ginsberg J., et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb. Haemost. 82 (1999) 947-952
3. Von Tempelhoff G.F., and Heilmann L. Antithrombotic therapy in gynecologic surgery and gynecologic oncology. Hematol. Oncol. Clin. North Am. 14 (2000) 1151-1169 ix.
4. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349 (2003) 146-153
5. Lee A.Y., Rickles F.R., Julian J.A., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol. 23 (2005) 2123-2129
6. Klerk C.P., Smorenburg S.M., Otten H.M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 23 10 (2005) 2130-2135
7. Kakkar A.K., Levine M.N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 22 (2004) 1944-1948
8. Lebeau B., Chastang C., Brechot J.M., et al., "Petites Cellules" Group. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 74 (1994) 38-45
9. Altinbas M., Coskun H.S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost. 2 (2004) 1266-1271
10. Fareed J., Hoppensteadt D., Schultz C., et al. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Curr. Pharm. Des. 10 (2004) 983-999
11. Bauer K.A., and Rosenberg R.D. Role of antithrombin III as a regulator of in vivo coagulation. Semin. Hematol. 28 (1991) 10-18
12. Harenberg J. Pharmacology of low molecular weight heparins. Semin. Thromb. Hemost. 16 Suppl. (1990) 12-18
13. Bauer K.A., and Rosenberg R.D. Activation markers of coagulation. Baillieres Clin. Haematol. 7 (1994) 523-540
14. Danielsson A., Raub E., Lindahl U., and Bjork I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J. Biol. Chem. 261 (1986) 15467-15473
15. Boneu B., Caranobe C., Cadroy Y., et al. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin. Thromb. Hemost. 14 (1988) 18-27
16. Hirsh J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 (2001) 64S-94S
17. Fransson L.A., and Carlstedt I. Alkaline and smith degradation of oxidized dermatan sulphate-chondroitin sulphate copolymers. Carbohydr. Res. 36 (1974) 349-358
18. Conrad H.E., and Guo Y. Structural analysis of periodate-oxidized heparin. Adv. Exp. Med. Biol. 313 (1992) 31-36
19. Irimura T., Nakajima M., and Nicolson G.L. Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry 25 (1986) 5322-5328
20. Vlodavsky I., Mohsen M., Lider O., et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 14 (1994) 290-302
21. Yoshitomi Y., Nakanishi H., Kusano Y., et al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett. 207 (2004) 165-174
22. Sciumbata T., Caretto P., Pirovano P., et al. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Invasion Metastasis 16 (1996) 132-143
23. Poggi A., Rossi C., Casella N., et al. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide. Semin. Thromb. Hemost. 28 (2002) 383-392
24. Back N., and Steger R. Effect of aprotinin, EACA and heparin on growth and vasopeptide system of Murphy-Sturm lymphosarcoma. Eur. J. Pharmacol. 38 (1976) 313-319
25. Ohkoshi M., Akagawa T., and Nakajima M. Effects of serine protease inhibitor FOY-305 and heparin on the growth of squamous cell carcinoma. Anticancer Res. 13 (1993) 963-966
26. Owen Jr. C.A. Anticoagulant treatment of rats with Walker 256 carcinosarcoma. J. Cancer Res. Clin. Oncol. 104 (1982) 191-193
27. Chan S.Y., and Pollard M. Metastasis-enhancing effect of heparin and its relationship to a lipoprotein factor. J. Natl. Cancer Inst. 64 (1980) 1121-1125
28. Lapierre F., Holme K., Lam L., et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 6 (1996) 355-366
29. Ono K., Ishihara M., Ishikawa K., et al. Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung. Br. J. Cancer 86 (2002) 1803-1812
30. Retik A.B., Arons M.S., Ketcham A.S., and Mantel N. The effect of heparin on primary tumors and metastases. JSR II (1962) 49-53
31. Hagmar B. Effect of heparin, epsilon-aminocaproic acid and coumarin on tumour growth and spontaneous metastasis formation. Pathol. Eur. 3 (1968) 622-630
32. Hagmar B. Tumour growth and spontaneous metastasis spread in two syngeneic systems. Acta Pathol. Microbiol. Scand. [A] 78 (1970) 131-142
33. Drago J.R., Weed P., and Fralisch A. The evaluation of heparin in control of metastasis of Nb rat androgen-insensitive prostate carcinoma. Anticancer Res. 4 (1984) 171-172
34. Drago J.R., and Lombard J.S. Metastasis in the androgen-insensitive Nb rat prostatic carcinoma system. J. Surg. Oncol. 28 (1985) 252-256
35. Milas L., Hunter N., and Basic I. Treatment with cortisone plus heparin or hexuronyl hexoaminoglycan sulfates of murine tumors and their lung deposits. Clin. Exp. Metastasis 3 (1985) 247-255
36. Lee A.E., Rogers L.A., Longcroft J.M., and Jeffery R.E. Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid. Clin. Exp. Metastasis 8 (1990) 165-171
37. Antachopoulos C.T., Gagos S., Iliopoulos D.C., et al. Low-dose heparin treatment does not inhibit SW480 human colon cancer growth and metastasis in vivo. In Vivo 10 (1996) 527-531
38. Smorenburg S.M., Vink R., te Lintelo M., et al. In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis. Clin. Exp. Metastasis 17 (1999) 451-456
39. Bobek V., Boubelik M., Fiserova A., et al. Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer 47 (2005) 215-223
40. Goldstein D.S., Lu M.L., Hattori T., et al. Inhibition of peritoneal tumor-cell implantation: model for laparoscopic cancer surgery. J. Endourol. 7 (1993) 237-241
41. Jacobi C.A., Ordemann J., Bohm B., et al. Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. Am. J. Surg. 174 (1997) 359-363
42. Jacobi C.A., Peter F.J., Wenger F.A., Ordemann J., and Muller J.M. New therapeutic strategies to avoid intra- and extraperitoneal metastases during laparoscopy: results of a tumor model in the rat. Dig. Surg. 16 (1999) 393-399
43. Neuhaus S.J., Ellis T., Jamieson G.G., and Watson D.I. Experimental study of the effect of intraperitoneal heparin on tumour implantation following laparoscopy. Br. J. Surg. 86 (1999) 400-404
44. Eshraghi N., Swanstrom L.L., Bax T., et al. Topical treatments of laparoscopic port sites can decrease the incidence of incision metastasis. Surg. Endosc. 13 (1999) 1121-1124
45. Pross M., Lippert H., Misselwitz F., et al. Low-molecular-weight heparin (reviparin) diminishes tumor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadeno-carcinoma cells in rats after laparoscopy. Thromb. Res. 110 (2003) 215-220
46. Pross M., Lippert H., Nestler G., et al. Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study. Int. J. Colorectal Dis. 19 (2004) 143-146
47. Amirkhosravi A., Mousa S.A., Amaya M., and Francis J.L. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J. Thromb. Haemost. 1 (2003) 1972-1976
48. Nagawa H., Paris P., Chauffert B., and Martin F. Treatment of experimental liver metastases in the rat by continuous intraportal infusion of 5-fluorouracil and heparin: a pilot study. Anticancer Drugs 1 (1990) 149-156
49. Mook O.R., Van Marle J., Vreeling-Sindelarova H., et al. Visualization of early events in tumor formation of eGFP-transfected rat colon cancer cells in liver. Hepatology 38 (2003) 295-304
50. Beuth J., Ko H.L., Uhlenbruck G., and Pulverer G. Combined immunostimulation (Propionibacterium avidum KP 40) and anticoagulation (heparin) prevents metastatic lung and liver colonization in mice. J. Cancer Res. Clin. Oncol. 113 (1987) 359-362
51. Lee A.E., Rogers L.A., Jeffery R.E., and Longcroft J.M. Comparison of metastatic cell lines derived from a murine mammary tumour, and reduction of metastasis by heparin. Clin. Exp. Metastasis 6 (1988) 463-471
52. Miao H.Q., Elkin M., Aingorn E., et al. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int. J. Cancer 83 (1999) 424-431
53. Borsig L., Wong R., Feramisco J., et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 3352-3357
54. Poggi A., Rossi C., Casella N., et al. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide. Semin. Thromb. Hemost. 28 (2002) 383-392
55. Stevenson J.L., Choi S.H., and Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin. Cancer Res. 11 (2005) 7003-7011
56. Bereczky B., Gilly R., Raso E., et al. Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest. Clin. Exp. Metastasis 22 (2005) 69-76
57. Im J.H., Fu W., Wang H., et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 64 (2004) 8613-8619
58. Wang X., Wang M., Amarzguioui M., et al. Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int. J. Cancer 112 (2004) 994-1002
59. Jurasz P., Alonso-Escolano D., and Radomski M.W. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br. J. Pharmacol. 143 (2004) 819-826
60. Kim Y.J., Borsig L., Varki N.M., and Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 9325-9330
61. Camerer E., Qazi A.A., Duong D.N., et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104 (2004) 397-401
62. Karpatkin S., Pearlstein E., Ambrogio C., and Coller B.S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J. Clin. Invest. 81 (1988) 1012-1019
63. Cohen S.A., Trikha M., and Mascelli M.A. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol. Oncol. Res. 6 (2000) 163-174
64. Amirkhosravi A., Mousa S.A., Amaya M., et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb. Haemost. 90 (2003) 549-554
65. Dvorak H.F., Nagy J.A., Berse B., et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann. N. Y. Acad. Sci. 667 (1992) 101-111
66. Costantini V., and Zacharski L.R. Fibrin and cancer. Thromb. Haemost. 69 (1993) 406-414
67. Palumbo J.S., Kombrinck K.W., Drew A.F., et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96 (2000) 3302-3309
68. Broze Jr. G.J. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu. Rev. Med. 46 (1995) 103-112
69. Sandset P.M., and Abildgaard U. Extrinsic pathway inhibitor-the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 21 (1991) 219-239
70. Mousa S.A., and Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb. Haemost. 92 (2004) 627-633
71. Poggi A., Rossi C., Casella N., et al. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide. Semin. Thromb. Hemost. 28 (2002) 383-392
72. Hembrough T.A., Swartz G.M., Papathanassiu A., et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 63 (2003) 2997-3000
73. Gasic G.J. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 3 (1984) 99-114
74. Honn K.V., Tang D.G., and Crissman J.D. Platelets and cancer metastasis: a causal relationship?. Cancer Metastasis Rev. 11 (1992) 325-351
75. Nieswandt B., Hafner M., Echtenacher B., and Mannel D.N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59 (1999) 1295-1300
76. Subramaniam M., Saffaripour S., van de W.L., et al. Role of endothelial selectins in wound repair. Am. J. Pathol. 150 (1997) 1701-1709
77. Talbott G.A., Sharar S.R., Harlan J.M., and Winn R.K. Leukocyte-endothelial interactions and organ injury: the role of adhesion molecules. New Horiz. 2 (1994) 545-554
78. Cummings R.D., and Smith D.F. The selectin family of carbohydrate-binding proteins: structure and importance of carbohydrate ligands for cell adhesion. Bioessays 14 (1992) 849-856
79. Norgard-Sumnicht K.E., Varki N.M., and Varki A. Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. Science 261 (1993) 480-483
80. Koenig A., Norgard-Sumnicht K., Linhardt R., and Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J. Clin. Invest. 101 (1998) 877-889
81. Nelson R.M., Cecconi O., Roberts W.G., et al. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82 (1993) 3253-3258
82. Varki N.M., and Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin. Thromb. Hemost. 28 (2002) 53-66
83. Nakajima M., Irimura T., and Nicolson G.L. Heparanases and tumor metastasis. J. Cell Biochem. 36 (1988) 157-167
84. Vlodavsky I., Korner G., Ishai-Michaeli R., et al. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev. 9 (1990) 203-226
85. Vlodavsky I., Goldshmidt O., Zcharia E., et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin. Cancer Biol. 12 (2002) 121-129
86. Maxhimer J.B., Quiros R.M., Stewart R., et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 132 (2002) 326-333
87. Friedmann Y., Vlodavsky I., Aingorn H., et al. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am. J. Pathol. 157 (2000) 1167-1175
88. Ginath S., Menczer J., Friedmann Y., et al. Expression of heparanase, Mdm2, and erbB2 in ovarian cancer. Int. J. Oncol. 18 (2001) 1133-1144
89. Gohji K., Hirano H., Okamoto M., et al. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int. J. Cancer 95 (2001) 295-301
90. Koliopanos A., Friess H., Kleeff J., et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 61 (2001) 4655-4659
91. Bitan M., Polliack A., Zecchina G., et al. Heparanase expression in human leukemias is restricted to acute myeloid leukemias. Exp. Hematol. 30 (2002) 34-41
92. Takahashi H., Ebihara S., Okazaki T., et al. Clinical significance of heparanase activity in primary resected non-small cell lung cancer. Lung Cancer 45 (2004) 207-214
93. Yang Y., Macleod V., Bendre M., et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 105 (2005) 1303-1309
94. Ishai-Michaeli R., Eldor A., and Vlodavsky I. Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Regul. 1 (1990) 833-842
95. Whitelock J.M., Murdoch A.D., Iozzo R.V., and Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 271 (1996) 10079-10086
96. Sanderson R.D., Yang Y., Suva L.J., and Kelly T. Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol. 23 (2004) 341-352
97. Elkin M., Ilan N., Ishai-Michaeli R., et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J. 15 (2001) 1661-1663
98. Vlodavsky I., and Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108 (2001) 341-347
99. Kato M., Wang H., Kainulainen V., et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med. 4 (1998) 691-697
100. Parish C.R., Coombe D.R., Jakobsen K.B., Bennett F.A., and Underwood P.A. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases. Int. J. Cancer 40 (1987) 511-518
101. Vlodavsky I., Friedmann Y., Elkin M., et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5 (1999) 793-802
102. Poggi A., Rossi C., Casella N., et al. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide. Semin. Thromb. Hemost. 28 (2002) 383-392
103. Colin S., Jeanny J.C., Mascarelli F., et al. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. Mol. Pharmacol. 55 (1999) 74-82
104. Collen A., Smorenburg S.M., Peters E., et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res. 60 (2000) 6196-6200
105. D'Amore P.A. Capillary growth: a two-cell system. Semin. Cancer Biol. 3 (1992) 49-56
106. Folkman J., Weisz P.B., Joullie M.M., Li W.W., and Ewing W.R. Control of angiogenesis with synthetic heparin substitutes. Science 243 (1989) 1490-1493
107. Soker S., Goldstaub D., Svahn C.M., et al. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors. Biochem. Biophys. Res. Commun. 203 (1994) 1339-1347
108. Lepri A., Benelli U., Bernardini N., et al. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J. Ocul. Pharmacol. 10 (1994) 273-280
109. Jayson G.C., and Gallagher J.T. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br. J. Cancer 75 (1997) 9-16
110. Kragh M., Binderup L., Vig Hjarnaa P.J., et al. Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol. Rep. 14 (2005) 99-104
111. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351 (2004) 781-791
112. Cristofanilli M., Hayes D.F., Budd G.T., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23 (2005) 1420-1430